We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
05 Sep 2020 - 09 Sep 2020
Virtual Venue

Immunoassay May Help Identify Pediatric Lyme Arthritis

By LabMedica International staff writers
Posted on 07 Jan 2020
Print article
Image: The Diagnostic Performance of C6 Enzyme Immunoassay for Lyme Arthritis has been evaluated (Photo courtesy of Lonnie R. Marcum, PT, BSHCA)
Image: The Diagnostic Performance of C6 Enzyme Immunoassay for Lyme Arthritis has been evaluated (Photo courtesy of Lonnie R. Marcum, PT, BSHCA)
In the USA, Lyme arthritis is the most common feature of late stage infection with the tick-borne spirochete, Borrelia burgdorferi, usually beginning months after the initial tick bite. Patients with Lyme arthritis have intermittent or persistent attacks of joint swelling and pain in one or a few large joints, especially the knee, usually over a period of several years, without prominent systemic manifestations.

In Lyme disease endemic areas, initial management of children with arthritis can be challenging because diagnostic tests take several days to return results, leading to potentially unnecessary invasive procedures. Synovial fluid polymerase chain reaction (PCR) testing for B. burgdorferi DNA is often positive prior to treatment, but it is not a reliable marker of spirochetal eradication after antibiotic therapy.

Doctors at the Boston Children's Hospital (Boston, MA, USA) and their colleagues examined the role of the C6 peptide enzyme immunoassay (EIA) test to guide initial management of children with acute arthritis undergoing evaluation for Lyme disease presenting to a participating Pedi Lyme Net emergency department (2015–2019). They defined Lyme arthritis with a positive or equivocal C6 EIA test result followed by a positive supplemental immunoblot result and defined septic arthritis as a positive synovial fluid culture result or a positive blood culture result with synovial fluid pleocytosis.

The scientists reported that of the 911 study patients, 211 children (23.2%) had Lyme arthritis, 11 (1.2%) had septic arthritis, and 689 (75.6%) had other inflammatory arthritis. A positive or equivocal C6 EIA result had a sensitivity of 100% (211/211) and specificity of 94.2% (661/700) for Lyme arthritis. None of the 250 children with a positive or equivocal C6 EIA result had septic arthritis, although 75 children underwent diagnostic arthrocentesis and 27 underwent operative joint washout.

Lise Nigrovic, MD, MPH, an assistant professor of Pediatrics and co-author of the study, said, “We demonstrated that the C6 EIA test, a previously approved first-tier test for Lyme disease, with results available within a few hours, could be used to safely guide initial management for children with inflamed joints to avoid unnecessary invasive procedures for children with Lyme arthritis.”

The authors concluded that in Lyme disease endemic areas, a C6 EIA result could be used to guide initial clinical decision-making, without misclassifying children with septic arthritis. The study was published in the December, 2019 issue of the journal Pediatrics.

Related Links:
Boston Children's Hospital

Print article


Molecular Diagnostics

view channel
Image: The NovaSeq 6000 Sequencing System offers high-throughput sequencing across a broad range of applications (Photo courtesy of Illumina).

Somatic Evolution Identified in Non-Neoplastic IBD-Affected Colon

Inflammatory bowel disease (IBD) is a debilitating disease characterized by repeated flares of intestinal inflammation. The two major subtypes of IBD, Crohn’s disease (CD) and ulcerative colitis (UC) are... Read more

Industry News

view channel
Image: ChemWell RPR Analyzer (Photo courtesy of Awareness Technology, Inc.)

Awareness Technology Announces ChemWell RPR Analyzer - The Most Significant Innovation in Syphilis Testing in Last 30 Years

Awareness Technology, Inc. (Palm City, FL, USA) has announced the most significant innovation in syphilis testing in the last 30 years with the launch of the ChemWell RPR automated nontreponemal analyzer... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.